Senseonics Holdings, Inc. (NYSE:SENS) CFO Frederick T. Sullivan Purchases 124,933 Shares

Senseonics Holdings, Inc. (NYSE:SENS) CFO Frederick T. Sullivan purchased 124,933 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Senseonics Stock Up 3.6 %

Shares of Senseonics stock opened at $0.45 on Friday. The firm has a market cap of $265.99 million, a price-to-earnings ratio of -3.44 and a beta of 0.77. The stock has a 50-day simple moving average of $0.33 and a 200-day simple moving average of $0.38. Senseonics Holdings, Inc. has a 52-week low of $0.25 and a 52-week high of $0.75. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Institutional Trading of Senseonics

A number of institutional investors have recently added to or reduced their stakes in SENS. FMR LLC increased its stake in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Senseonics in the third quarter worth $117,000. Symmetry Partners LLC bought a new stake in Senseonics in the third quarter worth $164,000. Cubist Systematic Strategies LLC increased its position in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after buying an additional 85,501 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares in the last quarter. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on SENS. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th. StockNews.com initiated coverage on Senseonics in a report on Tuesday, December 10th. They set a “sell” rating for the company.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.